Vimian Group enters partnership with biotechnology company Angany Inc. to develop novel vaccines for allergy and atopic dermatitis in companion animals – marketscreener.com

Just another WordPress site

Vimian Group enters partnership with biotechnology company Angany Inc. to develop novel vaccines for allergy and atopic dermatitis in companion animals – marketscreener.com

Gross sales 2021 169 M
190 M
190 M Internet income 2021 20,4 M
22,9 M
22,9 M Internet Debt 2021 78,0 M
87,6 M
87,6 M P/E ratio 2021 133x Yield 2021 Capitalization 3 549 M
4 002 M
3 987 M EV / Gross sales 2021 21,5x EV / Gross sales 2022 16,2x Nbr of Staff 450 Free-Float 43,2%

Chart VIMIAN GROUP AB (PUBL)


Interval : Auto.2 months3 months6 months9 months1 yr2 yrs5 yrs10 yrsMax.


Interval : DayWeek

Technical evaluation trfinishs VIMIAN GROUP AB (PUBL)

Brief Time period Mid-Time period Prolonged term Trfinishs Impartial Impartial Impartial

Income Assertion Evolution

Please allow JavaScript in your browser’s settings To make the most of dynamic charts.

Promote

Buy

Imply consensus BUY Quantity of Analysts 5 Final Shut Worth
9,12 €
Common goal price
11,81 €
Unfold / Common Target 29,5%

Please allow JavaScript in your browser’s settings To make the most of dynamic charts.

Source: https://www.marketscreener.com/quote/stock/VIMIAN-GROUP-AB-PUBL-123894241/news/Vimian-Group-enters-partnership-with-biotechnology-company-Angany-Inc-to-develop-novel-vaccines-for-37108927/

 

Leave a Reply

Your email address will not be published. Required fields are marked *